Joanne Willey

  • Citations Per Year
Learn More
286 Background: Since 2005 we at Xcenda, LLC have studied prescribing plans of American medical oncologists for first-line therapy in patients with MPC. In 2008 we reported the steady growth of prescribing plans for the gemcitabine-erlotinib (GE) combination from 23% in late 2005 to 46% in 2007. In 2007, gemcitabine (G) alone was the second most common(More)
BACKGROUND Etoposide-platinum doublet therapy has been the American standard first-line management for patients with small cell lung cancer for more than a decade. In the 1990s, Japanese investigators developed a regimen of irinotecan-cisplatin for extensive-stage patients and, in one head-to-head trial, the irinotecan therapy produced a statistically(More)
e18022 Background: In 9/07, Scagliotti et al reported that Pem-Plat produced superior OS vs. gem-plat as 1st line therapy in pts. with stage IV lung nonsquamous histologic subtypes of NSCLC. Subsequently other studies have also shown the optimized impact of pem-based treatment regimens in this same subgroup. Pem received a U.S. FDA indication as part of 1st(More)
BACKGROUND Evidence supporting optimal treatment sequencing in relapsed/refractory multiple myeloma (RRMM) patients requiring multiple therapy lines is lacking. METHODS Using retrospective chart data, this study describes real-world RRMM treatment patterns and related progression-free survival (PFS) in US community oncology clinics. RESULTS Bortezomib ±(More)
Production of recombinant Limulus endotoxin neutralizing protein (rENP) was attained with the GS115 methylotrophic strain of Pichia pastoris transformed with a plasmid, bearing multiple ENP gene copies. The synthetic gene for Limulus ENP was cloned into the integrative plasmid pAO815 under the control of a methanol-inducible promoter. Clones containing a(More)
BACKGROUND Practicing oncologists are expected to easily assimilate large amounts of rapidly evolving clinical data. We hypothesized that U.S. oncologists rapidly familiarize themselves with new, practice-relevant, phase III clinical trial data. We tested this hypothesis in relation to the release of phase III data from the Eastern Cooperative Oncology(More)
BACKGROUND Real-world evidence is lacking on the impact of bevacizumab added to carboplatin/paclitaxel (Bev + CP) therapy versus CP alone for patients with non-squamous non-small cell lung cancer (NS-NSCLC), particularly in those excluded from clinical trials. METHODS This is a retrospective electronic medical record analysis of patients who received(More)
PURPOSE To evaluate case-based choices selected from among preselected options for adjuvant therapy management in patients with completely resected non-small-cell lung cancer (NSCLC). METHODS In a series of meetings in which US oncologists participated in case-based discussions, market research data were acquired using audience response keypad technology.(More)
e19046 Background: Selection of oral EGFR inhibitors or chemotherapy as 2nd line in patients with NSCLC may be influenced by patients' performance status (PS), smoking status, gender; tumor histology; tolerance/response to 1st-line Rx; and patient expectations/desires. METHODS Between February '07 and October '08, we used a core case scenario of stage IV(More)